| Item Type | Name |
|
Concept
|
Hepatocyte Growth Factor
|
|
Academic Article
|
Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition.
|
|
Academic Article
|
Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer.
|
|
Academic Article
|
c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention.
|
|
Academic Article
|
Activation of HGF/c-Met pathway contributes to the reactive oxygen species generation and motility of small cell lung cancer cells.
|
|
Academic Article
|
c-Met: structure, functions and potential for therapeutic inhibition.
|
|
Academic Article
|
c-Met and hepatocyte growth factor: potential as novel targets in cancer therapy.
|
|
Academic Article
|
Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma.
|
|
Academic Article
|
Lysophosphatidic acid modulates c-Met redistribution and hepatocyte growth factor/c-Met signaling in human bronchial epithelial cells through PKC delta and E-cadherin.
|
|
Academic Article
|
Fyn is downstream of the HGF/MET signaling axis and affects cellular shape and tropism in PC3 cells.
|
|
Academic Article
|
Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion.
|
|
Academic Article
|
Inhibition of MET receptor tyrosine kinase and its ligand hepatocyte growth factor.
|
|
Academic Article
|
MET, HGF, EGFR, and PXN gene copy number in lung cancer using DNA extracts from FFPE archival samples and prognostic significance.
|
|
Academic Article
|
MET and phosphorylated MET as potential biomarkers in lung cancer.
|
|
Academic Article
|
Inhibition of MET receptor tyrosine kinase and its ligand hepatocyte growth factor.
|
|
Academic Article
|
c-Met is a potentially new therapeutic target for treatment of human melanoma.
|
|
Academic Article
|
Altered membrane fluidity in rat hepatocytes during endotoxic shock.
|
|
Academic Article
|
Haptoglobin alpha-subunit and hepatocyte growth factor can potentially serve as serum tumor biomarkers in small cell lung cancer.
|
|
Academic Article
|
CD44 regulates hepatocyte growth factor-mediated vascular integrity. Role of c-Met, Tiam1/Rac1, dynamin 2, and cortactin.
|
|
Academic Article
|
RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma.
|
|
Academic Article
|
Role of MetMAb (OA-5D5) in c-MET active lung malignancies.
|
|
Academic Article
|
Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence.
|
|
Academic Article
|
MET as a possible target for non-small-cell lung cancer.
|
|
Academic Article
|
Critical role of S1PR1 and integrin ß4 in HGF/c-Met-mediated increases in vascular integrity.
|
|
Academic Article
|
Role of c-Met/phosphatidylinositol 3-kinase (PI3k)/Akt signaling in hepatocyte growth factor (HGF)-mediated lamellipodia formation, reactive oxygen species (ROS) generation, and motility of lung endothelial cells.
|
|
Academic Article
|
Role of PAX8 in the regulation of MET and RON receptor tyrosine kinases in non-small cell lung cancer.
|
|
Academic Article
|
Role played by paxillin and paxillin tyrosine phosphorylation in hepatocyte growth factor/sphingosine-1-phosphate-mediated reactive oxygen species generation, lamellipodia formation, and endothelial barrier function.
|
|
Academic Article
|
MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale.
|
|
Grant
|
Novel Targeted Therapy in Pancreatic Cancer
|
|
Grant
|
Studies of a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC)
|